☆ 4.3 Article

Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting

CLINICAL BREAST CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

Olivia Pagani et al.

Summary: The combined analysis of SOFT-TEXT compared the outcomes of 4,690 premenopausal women with ER/PgR+ early breast cancer randomly assigned to exemestane + OFS or tamoxifen + OFS. Exemestane + OFS showed significant improvement in DFS and DRFI, but not overall survival, compared to tamoxifen + OFS. This study provides guidance for selecting patients who may benefit from exemestane over tamoxifen in the setting of OFS.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Ann H. Partridge et al.

Summary: This study evaluated the risk of breast cancer recurrence among young breast cancer patients who temporarily discontinued hormone therapy to attempt pregnancy. The results showed that this interruption in therapy did not increase the risk of breast cancer events.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

S. Paluch-Shimon et al.

Summary: This manuscript summarizes the ESO-ESMO international consensus recommendations for the management of breast cancer, and is also endorsed by EUSOMA.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

N. Harbeck et al.

Summary: Adjuvant abemaciclib combined with endocrine therapy significantly improved invasive disease-free survival in patients with early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic but did not affect the benefits of abemaciclib. The robust treatment benefit of abemaciclib extended beyond the planned 2-year treatment period.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women

Lindsay J. Collin et al.

Summary: This study evaluated the association between early discontinuation of endocrine therapy and breast cancer recurrence in premenopausal women. The results showed a higher rate of recurrence in women who discontinued endocrine therapy compared to those who completed the recommended treatment. These findings emphasize the importance of clinical follow-up and behavioral interventions to support the persistence of adjuvant endocrine therapy in preventing breast cancer recurrence.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Meeting Abstract Oncology

Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR plus ) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis

M. Bellet et al.

CANCER RESEARCH (2019)

Add to Collection

Article Medicine, General & Internal

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

P. A. Francis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Hongchao Pan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

Richard G. Gray et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress

Hyun-Ah Kim et al.

BMC CANCER (2016)

Add to Collection

Article Oncology

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

Meredith M. Regan et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression

Harold J. Burstein et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Review Oncology

The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer

Lorenzo Rossi et al.

BREAST CARE (2015)

Add to Collection

Article Medicine, General & Internal

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Prudence A. Francis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Olivia Pagani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Mathematical & Computational Biology

The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments

Peter C. Austin

STATISTICS IN MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies et al.

LANCET (2013)

Add to Collection

Article Oncology

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer

Emilio Bria et al.

LUNG CANCER (2009)

Add to Collection

Article Medicine, General & Internal

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Michael Gnant et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.